CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.75 Average Price Target from Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has received a consensus rating of "Moderate Buy" from the seventeen ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $71.75.

A number of research analysts have recently weighed in on CRSP shares. HC Wainwright reissued a "buy" rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a report on Friday, June 27th. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Wall Street Zen upgraded CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Needham & Company LLC reiterated a "buy" rating and set a $81.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, July 8th. Finally, Chardan Capital reiterated a "buy" rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, June 26th.

Insiders Place Their Bets

In related news, Director Simeon George bought 989,812 shares of the firm's stock in a transaction that occurred on Wednesday, July 16th. The stock was purchased at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the acquisition, the director owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. This trade represents a 133.69% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the sale, the insider directly owned 6,068 shares of the company's stock, valued at $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.30% of the company's stock.

Institutional Trading of CRISPR Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CRSP. PFG Investments LLC increased its position in CRISPR Therapeutics by 23.9% during the 2nd quarter. PFG Investments LLC now owns 12,896 shares of the company's stock worth $627,000 after purchasing an additional 2,487 shares during the period. Janney Montgomery Scott LLC increased its position in CRISPR Therapeutics by 26.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 13,585 shares of the company's stock worth $661,000 after purchasing an additional 2,882 shares during the period. Ipswich Investment Management Co. Inc. increased its position in CRISPR Therapeutics by 1.7% during the 2nd quarter. Ipswich Investment Management Co. Inc. now owns 24,968 shares of the company's stock worth $1,214,000 after purchasing an additional 425 shares during the period. Perigon Wealth Management LLC increased its position in CRISPR Therapeutics by 9.2% during the 2nd quarter. Perigon Wealth Management LLC now owns 18,312 shares of the company's stock worth $891,000 after purchasing an additional 1,538 shares during the period. Finally, AdvisorNet Financial Inc increased its position in CRISPR Therapeutics by 20.9% during the 2nd quarter. AdvisorNet Financial Inc now owns 6,133 shares of the company's stock worth $298,000 after purchasing an additional 1,060 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP traded up $10.04 during trading on Wednesday, hitting $65.13. The company had a trading volume of 10,155,091 shares, compared to its average volume of 1,994,222. The stock has a market cap of $5.62 billion, a price-to-earnings ratio of -14.41 and a beta of 1.82. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $66.49. The company has a fifty day simple moving average of $44.67 and a two-hundred day simple moving average of $41.86.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same period in the previous year, the firm earned ($1.43) earnings per share. The business's quarterly revenue was up 71.6% on a year-over-year basis. On average, equities research analysts anticipate that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.